Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 162 recruiting now early-phase tilt #14 of 28,707 conditions

Colorectal Cancer: early-phase trial registry

162 of 394 indexed Colorectal Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #14 of 28,707 conditions by registered trial count.

394 US clinical trials · 162 currently recruiting · #14 of 28,707 conditions by registered trial count

Colorectal Cancer: 394 US clinical trials tracked, 162 recruiting.

Colorectal Cancer is the subject of 394 registered US clinical trials on ClinicalTrials.gov, 162 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 201 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 22 of these trials.

Enrollment posture brief

Registry condition colorectal-cancer

OPEN 162 | RECR 41% | LATE 13 | EARLY 201 | RANK #14 | SPON 22

Nearest open-share peer: Erectile Dysfunction (41% recruiting · 34 trials)

Heart Failure41.1%Colorectal Cancer (this)41%Anxiety40.3%Pain28.1%Asthma18.5%
Open-enrollment share among volume-matched conditions near Colorectal Cancer

Colorectal Cancer lists 162 open slots (41% of 394 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Colorectal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Colorectal Cancer is recruiting above its size-band peers.

    162 of 394 indexed trials (41.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Colorectal Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 22 of 394 trials (5.6%). 222 distinct sponsors appear on at least one study for this condition label.

  3. Typical Colorectal Cancer enrolment sits around 132 participants.

    Median target enrolment is 132 among the 382 trials that report a genuine target (sentinel values excluded). 162 of those (42.4%) plan for fewer than 100 participants.

  4. Colorectal Cancer research is mostly interventional.

    323 interventional and 71 observational studies make up this index (82% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1132Phase 269Phase 310Phase 43

Open and recent trials

394 total, page 3 of 8

RECRUITING 120 participants

Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer

Memorial Sloan Kettering Cancer Center

NCT04812912

RECRUITING Phase 2 120 participants

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

Criterium

NCT06992258

RECRUITING NA 120 participants

Personalized Health Self-Management Training for Colorectal Cancer Survivors

University of Southern California

NCT05984589

RECRUITING Phase 1 117 participants

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

Anwaar Saeed

NCT03539822

RECRUITING Phase 1 113 participants

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Fate Therapeutics

NCT07216105

RECRUITING Phase 1 112 participants

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Perspective Therapeutics

NCT06710756

RECRUITING 105 participants

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

AstraZeneca

NCT06973161

RECRUITING Phase 1 105 participants

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

Rgenta Therapeutics

NCT06462183

RECRUITING NA 100 participants

Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis

Case Comprehensive Cancer Center

NCT07044362

RECRUITING NA 100 participants

The Florida ASCENT Study

University of Florida

NCT07042243

RECRUITING Phase 1 100 participants

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

Apollo Therapeutics

NCT06399757

RECRUITING Phase 1 99 participants

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

Roswell Park Cancer Institute

NCT03965234

RECRUITING Phase 2 97 participants

Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer

Virginia Commonwealth University

NCT06728072

RECRUITING NA 90 participants

Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer

Washington University School of Medicine

NCT04339374

RECRUITING Phase 2 90 participants

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

Kahr Bio Australia Pty

NCT07235293

RECRUITING Phase 2 87 participants

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Vyriad

NCT04291105

RECRUITING NA 84 participants

Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial

Dana-Farber Cancer Institute

NCT06202183

RECRUITING 80 participants

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

Memorial Sloan Kettering Cancer Center

NCT04668872

RECRUITING Phase 1 80 participants

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

Massachusetts General Hospital

NCT05692024

RECRUITING Phase 1 80 participants

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

Cartography Biosciences

NCT07321106

RECRUITING Phase 1 80 participants

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

Angiex

NCT06440005

RECRUITING Phase 1 80 participants

Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery

University of Chicago

NCT06349590

RECRUITING Phase 1 78 participants

A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors

Crossignal Therapeutics

NCT06598007

RECRUITING Phase 1 78 participants

IDOV-Immune for Advanced Solid Tumors

ViroMissile

NCT06910657

RECRUITING Phase 4 78 participants

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Takeda

NCT06562543

RECRUITING Phase 1 71 participants

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Blue Earth Diagnostics

NCT07432633

RECRUITING Phase 2 70 participants

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

National Cancer Institute (NCI)

NCT05286814

RECRUITING Phase 1 66 participants

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

Lumicell

NCT02584244

RECRUITING Phase 1 61 participants

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Radiopharm Theranostics

NCT07189871

RECRUITING Phase 1 60 participants

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

BioEclipse Therapeutics

NCT04282044

RECRUITING Phase 2 60 participants

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)

SCRI Development Innovations

NCT07011576

RECRUITING Phase 1 54 participants

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06411691

RECRUITING Phase 1 53 participants

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

University of Chicago

NCT05200442

RECRUITING Phase 2 51 participants

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

University of California, Irvine

NCT06580002

RECRUITING NA 50 participants

Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial

Medical College of Wisconsin

NCT07227077

RECRUITING NA 48 participants

Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

NCT06731998

RECRUITING Phase 1 45 participants

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

Baylor College of Medicine

NCT03740256

RECRUITING Phase 2 44 participants

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06205836

RECRUITING Phase 2 43 participants

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Northwestern University

NCT05576896

RECRUITING Phase 1 42 participants

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

M.D. Anderson Cancer Center

NCT06358430

RECRUITING NA 40 participants

Resistance Exercise and Creatine in Colorectal Cancer

University of South Carolina

NCT06420726

RECRUITING Phase 2 40 participants

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

M.D. Anderson Cancer Center

NCT05411718

RECRUITING 40 participants

Precision-MRD: Prospective Observational Study of Biomarker-directed Systemic Therapy for Colorectal Cancer Patients With Minimal Residual Disease

M.D. Anderson Cancer Center

NCT06878131

RECRUITING NA 40 participants

The Food Environment, Microbial Cysteine Metabolism, and Cancer Disparities

Purdue University

NCT07086833

RECRUITING Phase 2 40 participants

Tislelizumab in People With Colorectal Cancer

Memorial Sloan Kettering Cancer Center

NCT06529523

RECRUITING NA 40 participants

The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial

Dana-Farber Cancer Institute

NCT06565052

RECRUITING Phase 1 38 participants

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

Hefei TG ImmunoPharma Co.

NCT05746897

RECRUITING NA 36 participants

Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer

Dartmouth-Hitchcock Medical Center

NCT05780684

RECRUITING Phase 1 33 participants

Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Zumutor Biologics

NCT06451497

RECRUITING Phase 2 32 participants

A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer

Memorial Sloan Kettering Cancer Center

NCT06130280

← Previous Page 3 of 8 Next →

Phase Distribution

PhaseTrial count
Phase 1 132
Phase 2 69
Phase 3 10
Phase 4 3

Named interventions

Most-linked intervention names on Colorectal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cetuximab Drug
15 trials
Oxaliplatin Drug
14 trials
Bevacizumab Drug
11 trials
irinotecan hydrochloride Drug
9 trials
fluorouracil Drug
9 trials
Irinotecan Drug
9 trials
leucovorin calcium Drug
8 trials
Leucovorin Drug
7 trials

US sites by state

Facility locations filed on Colorectal Cancer trials. A trial with sites in several states counts in each.

California 133 trials
New York 100 trials
Texas 98 trials
Florida 86 trials
Massachusetts 64 trials
Pennsylvania 57 trials
Tennessee 53 trials
Michigan 51 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Colorectal Cancer page

394 registered trials, 162 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Colorectal Cancer condition card totals 394 registered trials; most-linked intervention Cetuximab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.